R. Lyon

发表

Abstract 648: Optimization of a PEGylated glucuronide-auristatin linker for antibody-drug conjugates

P. Burke, P. Senter, Joseph Z. Hamilton, 2015 .

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

P. Burke, P. Senter, J. Hunter, 2015, Nature Biotechnology.

Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues.

P. Senter, R. Lyon, J. Setter, 2012, Methods in enzymology.

Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.

Kim K. Emmerton, D. Benjamin, N. Okeley, 2016, Cancer research.

Novel class of bivalent glutathione S-transferase inhibitors.

W. Atkins, R. Lyon, John J. Hill, 2003, Biochemistry.

Contribution of Nontarget Cells to the Disposition, Antitumor Activity, and Antigen-Independent Toxicity of Antibody–Drug Conjugates

R. Lyon, Fu Li, David W Meyer, 2021 .

An in vitro assay using cultured Kupffer cells can predict the impact of drug conjugation on in vivo antibody pharmacokinetics.

Joseph Z. Hamilton, J. Hunter, N. Okeley, 2020, Molecular pharmaceutics.

Antibody-conjugated drug assay for protease-cleavable antibody-drug conjugates.

D. Benjamin, S. Hengel, S. Alley, 2016, Bioanalysis.

A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.

P. Burke, P. Senter, D. Sussman, 2013, Bioconjugate chemistry.

Bivalent inhibitors of Glutathione-S-Transferases

W. Atkins, R. Lyon, J. Zebala, 2006 .

Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation.

P. Burke, R. Lyon, Julia H. Cochran, 2020, Toxicology and applied pharmacology.

Estradiol metabolites as isoform-specific inhibitors of human glutathione S-transferases.

C. Verlinde, D. Eaton, T. Monks, 2004, Chemico-biological interactions.

Glucuronide-Linked Antibody–Tubulysin Conjugates Display Activity in MDR+ and Heterogeneous Tumor Models

Kim K. Emmerton, A. Waight, P. Burke, 2018, Molecular Cancer Therapeutics.

Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody–Drug Conjugates

J. Nix, A. Waight, P. Senter, 2018, Molecular Cancer Therapeutics.

Abstract 3694: Relationship betweenin vivoantitumor activity of ADC and payload release in preclinical models

Kim K. Emmerton, D. Benjamin, N. Okeley, 2014 .

Drawing lessons from the clinical development of antibody-drug conjugates.

R. Lyon, 2018, Drug discovery today. Technologies.

Kinetic characterization of native and cysteine 112-modified glutathione S-transferase A1-1: reassessment of nonsubstrate ligand binding.

W. Atkins, R. Lyon, 2002, Biochemistry.

Self-assembly and gelation of oxidized glutathione in organic solvents.

W. Atkins, R. Lyon, W M Atkins, 2001, Journal of the American Chemical Society.

The Methylene Alkoxy Carbamate Self-Immolative Unit: Utilization for the Targeted Delivery of Alcohol-Containing Payloads with Antibody-Drug Conjugates.

Kim K. Emmerton, P. Senter, S. Jeffrey, 2016, Angewandte Chemie.

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

I. Bernstein, P. Burke, R. Walter, 2013, Blood.

Anti-CD30 diabody-drug conjugates with potent antitumor activity

P. Carter, H. Gerber, S. Alley, 2008, Molecular Cancer Therapeutics.

A coiled-coil masking domain for selective activation of therapeutic antibodies

Matthew R. Levengood, Vivian H. Trang, P. Senter, 2019, Nature Biotechnology.

Empowered Antibodies for Cancer Therapy

P. Senter, S. Alley, D. Sussman, 2011 .

Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

Robert Lyon, Charlotte F. McDonagh, Martha Anderson, 2008, Molecular Cancer Therapeutics.

A coiled-coil masking domain for selective activation of therapeutic antibodies

Matthew R. Levengood, Vivian H. Trang, P. Senter, 2019, Nature Biotechnology.

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

P. Senter, J. Hunter, S. Doronina, 2014, Nature Biotechnology.

Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux–positive Tumor Models

Kim K. Emmerton, A. Waight, P. Senter, 2020, Molecular Cancer Therapeutics.

Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates

P. Burke, P. Senter, Joseph Z. Hamilton, 2016, Molecular Cancer Therapeutics.

Snap-to-it probes: chelate-constrained nucleobase oligomers with enhanced binding specificity

R. Lyon, J. Zebala, D. Maeda, 2008, Nucleic acids research.

Abstract 4634: Engineered cysteine drug conjugates show potency and improved safety

D. Benjamin, D. Sussman, Martha E. Anderson, 2012 .

Abstract 4631: Anti-CD70 antibody-drug conjugates containing pyrrolobenzodiazepine dimers demonstrate robust antitumor activity

P. Burke, P. Senter, S. Jeffrey, 2012 .

Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability

P. Carter, D. Benjamin, S. Alley, 2018, Protein engineering, design & selection : PEDS.

Development of Novel Quaternary Ammonium Linkers for Antibody–Drug Conjugates

Kim K. Emmerton, A. Waight, P. Burke, 2016, Molecular Cancer Therapeutics.

A glutathione-based hydrogel and its site-selective interactions with water.

W. Atkins, R. Lyon, R. Mehta, 2005, Bioconjugate chemistry.

Stopped-flow kinetic analysis of the ligand-induced coil-helix transition in glutathione S-transferase A1-1: evidence for a persistent denatured state.

W. Atkins, R. Lyon, M. Dabrowski, 1999, Biochemistry.

Structure-activity relationships of tubulysin analogues.

A. Waight, P. Burke, P. Senter, 2020, Bioorganic & medicinal chemistry letters.

A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.

P. Burke, P. Senter, D. Sussman, 2013, Bioconjugate chemistry.